Study confirms HPV vaccine provides protection for nearly two decades
研究證實人類乳突病毒疫苗可提供近二十年的保護力
A major breakthrough in public health has arrived: new data confirms that the HPV vaccine provides robust protection for nearly two decades.
公共衛生領域出現重大突破：最新數據證實，人類乳突病毒（HPV）疫苗能提供長達近二十年的強健保護。
When given to pre-adolescents, the vaccine can reduce the risk of cervical cancer by 80–90%, making it a powerful tool for cancer prevention.
在青少年前期接種該疫苗，可降低80%至90%的子宮頸癌罹患風險，使其成為防癌的強大工具。
Real-world data from nations like Sweden and Scotland shows that mass immunization creates herd immunity, significantly reducing virus transmission.
瑞典和蘇格蘭等國的實證數據顯示，大規模免疫接種能產生群體免疫效應，顯著降低病毒傳播。
Beyond cervical cancer, the vaccine protects against various other cancers of the throat and reproductive areas.
除子宮頸癌外，該疫苗還能保護免受喉癌及其他生殖器官癌症的威脅。
With two decades of monitoring confirming its high safety profile, experts view this as a green light to push for global elimination of cervical cancer.
二十年的監測證實了其高度安全性，專家認為這是推動全球消滅子宮頸癌的綠燈。
By vaccinating early, we can stop cancer before it starts, proving that proactive healthcare is our strongest defense against disease.
透過及早接種，我們能在癌症發生前阻斷它，這證明了主動式醫療是我們對抗疾病的最強防線。
